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Abstract
Background: The relationship between loss-to-follow-up (LTFU) in HIV treatment and care programmes and psychosocial
factors, including self-reported stigma, is important to understand. This prospective cohort study explored stigma and LTFU
in treatment eligible adults who had yet not started antiretroviral therapy (ART).
Methods: Psychosocial, clinical and demographic data were collected at a baseline interview. Self-reported stigma was
measured with a multi-item scale. LTFU was defined as not attending clinic in the 90 days since last appointment or before
death. Data was collected between January 2009 and January 2013 and analysed using Cox Regression.
Results: 380 individuals were recruited (median time in study 3.35 years, total time at risk 1065.81 person-years). 203 were
retained (53.4%), 109 were LTFU (28.7%), 48 had died and were not LTFU at death (12.6%) and 20 had transferred out (5.3%).
The LTFU rate was 10.65 per 100 person-years (95% CI: 8.48–12.34). 362 individuals (95.3%) started ART. Stigma total score
(categorised in quartiles) was not significantly associated with LTFU in either univariable or multivariable analysis (adjusting
for other variables in the final model): second quartile aHR 0.77 (95%CI: 0.41–1.46), third quartile aHR 1.20(95%CI: 0.721–
2.04), fourth quartile aHR 0.62 (95%CI: 0.35–1.11). In the final multivariable model, higher LTFU rates were associated with
male gender, increased openness with friends/family and believing that community problems would be solved at higher
levels. Lower LTFU rates were independently associated with increased year of age, greater reliance on family/friends, and
having children.
Conclusions: Demographic and other psychosocial factors were more closely related to LTFU than self-reported stigma. This
may be consistent with high levels of social exposure to HIV and ART and with stigma affecting LTFU less than other stages
of care. Research and clinical implications are discussed.
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Introduction
South Africa has the largest HIV positive population in the
world with an estimated 5.6 million people [1]. Amongst those 15–
49 years of age, HIV prevalence is estimated at 18% [1]. South
Africa’s public sector antiretroviral (ART) programme began in
2004 and was serving approximately two million by the end of
2012 [2].
Loss-to-follow-up (LTFU) (non-attendance at scheduled clinic
visits) in HIV programmes in sub-Saharan Africa (SSA) is
important among those eligible for ART, given the risk of
mortality and morbidity, onward transmission and ART resistance
with inconsistent medication use [3].The broader concept of
‘attrition’ from care encompasses (a) loss to follow up (LTFU) (b)
death (c) transfer out - to a known ART programme and (d)
migration where further HIV care is not known. It is often difficult
to determine reasons for loss of care and, therefore, all-cause
attrition rates are usually reported rather than LTFU distinct from
death, transfer out or migration.
High levels of attrition from HIV programmes in SSA have
been reported in the period between the assessment of individuals
as ART eligible and treatment initiation [4,5]. For those who have
started ART, attrition rates of 23% at one year, 25% at two years
and 30% at three years in SSA have been estimated [6]. LTFU
rates of 14% at one year and 29% at three years in South Africa
for those on treatment have been reported [3].
A number of clinical, demographic and structural factors have
been shown to relate to higher rates of LTFU in individuals on
ART (or those eligible to start ART) in SSA. Clinical correlates of
higher LTFU include both lower [7], and higher CD4 count [8,9],
poorer adherence to ART [10] and TB co-infection [11,12].
Demographic correlates of LTFU include male gender [7,13],
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younger age [3,9,14], pregnancy for women [14], lower levels of
education [13], financial constraints [15], and migration [8,16].
Structural correlates include less distance to a tarred road [8], later
calendar year of ART initiation [9] and increased time on ART
[9].
Psychosocial predictors of LTFU have been assessed less
frequently, perhaps due to the relative difficulty of obtaining
relevant information. A recent qualitative study interviewed those
who were LTFU and found both intentional (e.g., dissatisfaction
with care, shame about returning to care after missed visits) and
unintentional (e.g., competing demands) reasons for LTFU, with
the reasons for missed visits changing over time [17].
One psychosocial factor that may be associated with LTFU is
stigma. For those infected with HIV, Earnshaw and Chaudoir [18]
describe three stigma processes - enacted stigma (perceptions of
discrimination from others in the community), anticipated stigma
(expectations of discrimination in the future), and internalized stigma
(endorsement of negative beliefs and feelings associated with HIV).
Explanatory models applied to retention in care have suggested a
role for stigma. For example, stigma is included as an affective
contextual factor in a model of HIV care initation and
maintenance (the situated Information Motivational Behavioral
Skills Model: IMB) [19].
The relationship between self-reported stigma and LTFU has
not been examined quantitatively in those eligible to start ART. In
SSA, stigma has been statistically associated with retention at some
of the other stages of the ‘cascade of care’. Higher levels of stigma
(measured using different multi-item scales) have been associated
with reduced levels of HIV testing in South Africa [20] and with
lower levels of ART adherence in east and southern Africa [21].
We present findings on the relationship between self-reported
stigma and LTFU from a prospective cohort study within an HIV
treatment and care programme in an area of high HIV prevalence
and widespread ART availability in KwaZulu-Natal, South Africa
[22]. We assessed individuals’ self-reported stigma after they had
been assessed and informed of their eligibilty for ART, followed
them up for a maximum of four years, and explored the
associations between this factor, a range of additional psychosocial,
demographic and medical factors and LTFU. We hypothesised
that higher levels of self-reported stigma would be related to higher
rates of LTFU.
Methods
Study design and location
The study used a prospective cohort design with recruitment
between January 6th 2009 and August 25th 2010 and follow-up
until January 13th 2013. It took place in the Hlabisa sub-district of
uMkhanyakude, a rural area of northern KwaZulu-Natal, South
Africa, with an HIV adult prevalence estimate of 24% [23]. ART
coverage of HIV-infected people in the community was estimated
to be 31% in 2011 [24] with evidence of a substantial reduction in
HIV-related mortality [25]. There are high rates of social exposure
to HIV and ART in the district. For example, a large proportion
of the population share household or living arrangements with
individuals in HIV treatment and care [26], with evidence of HIV
disclosure within social networks [27].
The HIV treatment and care programme began in 2004 and is
large scale and decentralized [28]. It implements National ART
guidelines, which until April 2010 denoted ART eligibility when
individuals had a CD4 count #200 cells/mm3 or a WHO stage 3
or 4 condition [29], between April 2010 and August 2011, CD4
count #350 cells/mm3 for pregnant women, active TB, a WHO
stage 3 or 4 condition [30], and from August 2011 onwards, CD4
count ,350 cells/mm3 and all MDR-TB patients [31]. Between
assessment as eligible to start and treatment initiation, individuals
attend three treatment literacy sessions (aside from pregnant
women, those with very low CD4 counts, stage 4 illness or with
TB). These sessions occur over a two-week period and are
conducted by treatment counsellors at the clinics, usually in
groups. The sessions are focused on ART regimens and adherence
to ART. Stigma is not addressed in these sessions. ART can be
initiated by nurses (since 2012) or doctors.
People who have initiated ART attend clinic every month when
they also see treatment counsellors to discuss adherence. These
guidelines changed to every two months in 2011 for clinically
stable individuals with virological suppression [31]. Tracking of
individuals by phone and home visits usually occurs for those who
have initiated ART and miss three consecutive appointments
(subject to holidays and resource constraints).
Participants
HIV positive participants taking part in a prospective cohort
study [22] and (a) recently assessed as ART eligible according to
South African ART guidelines at the time of inclusion in the study
(i.e., between January 2009 and August 2010) [29–31] (b) $18
years (c) attending one of three HIV clinics situated in the Africa
Centre Demographic Surveillance Area (DSA), were included in
this analysis. The DSA covers about one third of the Hlabisa
health subdistrict.
Potential participants were excluded if they were currently
pregnant, planned to leave the area within 12 months or had
previous ART use for $two weeks. Sampling for the study was
systematic: all individuals meeting the inclusion criteria were
approached. Individuals were recruited between receiving the
CD4 count that confirmed their eligibilty for ART and initiating
ART. Therefore, some participants had attended some or all of
the treatment literacy sessions. A general introduction to the study
was given each morning by study staff in the clinic waiting room.
Additional study instructions were targeted to individuals present-
ing for CD4 testing, who were asked to present themselves to a
study staff member when they returned for their CD4 results if
they were interested in joining the study. On meeting the study
staff member and after screening for eligibility, individuals were
taken through the study information sheet and informed consent
process [22]. Written consent was given for participation with
separate consent to link study data with HIV treatment and care
programme and DSA data.
Ethics
Ethical approval was obtained from the Biomedical Research
Ethics Committee at the University of KwaZulu-Natal (ref:
BF083/08), the KwaZulu-Natal Department of Health and the
London School of Hygiene and Tropical Medicine (ref 08/365).
Measurement of variables
Variables were collected from three sources: (1) a baseline
interview that took place on recruitment: questions that formed
this interview were translated into isiZulu and backtranslated into
English to ensure equivalence of meaning (2) routinely held
programme data held in a monthly updated database, and (3) DSA
data: demographic information is collected biannually and entered
into a DSA database for the approximately 90, 000 individuals
who are member of households within the area.
Variables were chosen due to observed relationships with
attrition or LTFU in previous studies or their potential relation-
ship with LTFU. The main psychosocial variables were:
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1. Stigma. 24 questions were adapted from Sayles et al [32] (e.g.,
‘I feel ashamed to tell people that I have HIV’) with the options ‘agree’,
‘disagree’ or ‘no opinion’. The choice of the final questions was
informed by a consultation process with isiZulu speaking
individuals from the same community as participants, who
gave advice on meaning and language. Scores were added to
form a scale with a total score (out of 72). Scale reliability was
good (a=0.75).
2. Reason for testing. Participants were asked what the main
reason was for deciding to test for HIV. A list of possible
reasons was provided. These were grouped into:
a. Self-initiated: non-sickness. e.g., ‘Easy access’, ‘Wanted to know
status’.
b. Self-initiated: sickness. e.g., ‘I was sick/having symptoms’.
c. Other-initiated. e.g., ‘pregnant/tested at antenatal clinic’, ‘partner
required I got tested’.
3. Social support. Five questions, derived from Myer et al [33],
covering frequency of contact with and reliance on family
members/friends, personal disclosure to friends/family, and
the availability of confidants were used. They were considered
as separate questions due to differences in response options and
low inter-item correlations (in comparison with Myer et al [33]
who summed the items to form a scale).
4. Social capital. This refers to an individual’s connections
(structural) and trust/reciprocity (cognitive) with others [34].
Questions were based on Pronyk et al [35]. Three structural
questions asked about frequency of time spent with neighbours,
frequency of crime in the neighbourhood and community
group participation. Two cognitive questions asked about
neighbours’ commitment to community projects, and prob-
lem-solving for community problems. These five questions
were considered separately due to differences in response
options and low inter-item correlations (in comparison with
Pronyk et al [35]who formed composite variables for each
dimension).
5. Antiretroviral Therapy. Three aspects were assessed:
a. Personal knowledge of others taking ART.
Figure 1. Outcome Flow Diagram.
doi:10.1371/journal.pone.0088235.g001
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Table 1. Univariable analysis: demographic and clinical variables and LTFU.
Number1 (%LTFU)
LTFU rate
(per 100 p/y) Hazard Ratio2(95% CI)
P value of
association with
LTFU (LRT)
Age in years ,27 60(38.3) 15.02 1.00 0.01
27–31 77(39.0) 14.36 0.94 (0.55–1.63)
32–37 88(26.1) 9.33 0.60 (0.34–1.07)
38–44 77 (29.9) 9.88 0.61 (0.34–1.09)
.44 78 (12.8) 4.46 0.28 (0.13–0.58)
Age in years (linear term) 0.96 (0.94–0.98) ,0.01
Gender Female 241 (27.8) 9.68 1.00 0.37
Male 139 (30.2) 11.23 1.19 (0.81–1.76)
Clinic 1 120 (26.7) 8.85 1.00 ,0.01
2 153(38.6) 14.74 1.99 (1.28–3.07)
3 107 (16.8) 5.92 0.71 (0.40–1.27)
Marital status Never married 299 (30.8) 11.08 1.00 0.08
Ever married (married,
divorced, separated or
widowed)
81 (21.0) 7.22 0.65 (0.89–1.08)
Number of current sexual
relationships
0 139(30.9) 11.85 1.00 0.19
$1 241(27.4) 9.39 0.77 (0.53–1.13)
Religion None 49 (34.7) 12.87 1.00 0.48
Zionist 120 (30.0) 10.41 0.73 (0.41–1.31)
Shembe 69 (23.2) 7.84 0.57 (0.29–1.13)
Christian 122 (29.5) 11.05 0.77 (0.43–1.38)
Other 20 (20.0) 6.88 0.48 (0.16–1.42)
Religion importance Not at all 68 (29.4) 10.58 1.00 0.63
Somewhat 68 (26.5) 9.15 0.76 (0.40–1.44)
Very 245 (29.0) 10.44 0.95 (0.58–1.57)
Employment No 283 (28.6) 10.50 1.00 0.45
Yes 97 (28.9) 9.52 0.85 (0.55–1.31)
Government grant (self) No 174 (28.7) 10.76 1.00 0.45
Yes 206 (28.6) 9.82 0.86 (0.59–1.26)
Government grant (household) No 140 (30.0) 11.21 1.00 0.49
Yes 240 (27.9) 9.69 0.87 (0.59–1.28)
Time since HIV diagnosis This month 59 (27.1) 10.13 1.00 0.91
,one year 194 (29.9) 10.74 1.10 (0.63–1.91)
1–2 years 57 (28.1) 9.69 0.98 (0.49–1.96)
3+ years 70 (27.1) 9.38 0.92 (0.47–1.79)
Highest Educational level3 ,1 year 24 (20.8) 7.41 1.00 0.02
Primary School 86 (17.4) 5.82 0.75 (0.27–2.05)
Secondary, not matric 148 (33.8) 11.75 1.56 (0.62–3.91)
Matric and higher 98 (34.7) 12.63 1.69 (0.66–4.32)
Number of children None 35 (40.0) 17.72 1.00 0.02
1 child 66 (27.3) 9.63 0.45 (0.22–0.90)
2 children 80 (30.0) 9.93 0.45 (0.23–0.87)
3 children 62 (40.3) 14.26 0.68 (0.36–1.32)
4+ children 137 (20.4) 7.31 0.35 (0.18–0.67)
On TB treatment at Initiation4 No 259 (25.9) 8.78 1.00 0.12
Yes 86 (27.9) 9.64 1.14 (0.71–1.81)
Don’t know 18 (38.9) 16.60 2.52 (1.15–5.50)
CD4 count (quartile)5 0–76 96 (30.2) 11.50 1.00 0.65
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b. HIV optimism. One question (adapted from Elford et al [36])
- ‘I am less worried about HIV now that treatment is available’: ‘agree’,
‘disagree’ or ‘no opinion’.
c. ART/HIV knowledge. Eight questions, e.g., ‘Sometimes ART
can cause side effects that make people feel worse’: ‘agree’, ‘disagree’ or
‘no opinion’. Scores were added to provide a total score to form
a scale (out of 24). Scale reliability was poor to fair (a=0.44).
6.Other baseline variables. Information was collected on
age, gender, number of current sexual relationships, employ-
ment, clinic, education, TB status, duration since HIV
diagnosis, marital status, religious affiliation and importance,
extent of HIV disclosure (the number of categories of those
disclosed to, e.g. partner, friend, family), partner satisfaction
(measured with a 10-item scale: a=0.75), most recent partner
(age differential, location, HIV disclosure and HIV status),
government grants and migration.
Outcomes
The ART programme database was used to define all outcomes,
with verification of outcome by cross-checking with the DSA
database and the study database. Participants were considered
LTFU if they had not attended clinic in the last 90 days, or in the
90 days before death, and excluded transfers out of the
programme. The entry date was the date of recruitment. The
end of observation date was the last clinic date (for LTFU) and the
death date (if the individual had not met the criteria for LTFU
before their death). People who were transferred out were
censored at last clinic visit and those who were retained in the
programme were censored at the study end date (13th January
2013).
Analysis
Analysis used STATA 11 [37]. Distributions of four quantitative
variables were examined for normality. ART knowledge and
partnership satisfaction were skewed (p,0.01 for both) and were
therefore categorised. Age was also skewed (p,0.01) and was
considered both as age bands and as a continuous variable in
univariable analysis. Stigma was normally distributed (p = 0.23).
This variable was considered as a continuous variable and also
grouped into quartiles (as linearity could not be assumed on the
basis of univariable analysis).
Univariable associations, using Cox Regression (to accommo-
date varying follow-up times) were carried out between LTFU and
(a) stigma (as a continuous variable and quartiles) (b) other baseline
variables. Multivariable analysis was then conducted, using Cox
Regression, with the inclusion of stigma quartiles (as the
categorical term was more closely related to LTFU than the
continuous variable), gender and age (as a continuous variable, to
preserve degrees of freedom and given the closer relationship to
LTFU than age bands). Additional variables with univariable
relationships with LTFU of p,0.10 were then added in
descending order of the strength of relationship with LTFU.
These variables were retained if they improved model fit (using
Likelihood Ratio Tests). Variables that were dropped during the
model building process were added to the final model to examine
whether they improved model fit (and were retained if they did so).
The proportional hazards assumption was tested for variables in
the final model by (1) splitting time in the study at the 50th centile
for attrition events - Likelihood Ratio Tests were used to test
whether rates differed between the time bands for each of the
variables in the final model (2) examining Kaplan Meier plots and
(3) testing Schoenfeld residuals [38]. Potential confounding
between variables in the final model was examined through
investigation of variables whose effect size estimates showed large
changes between univariable and adjusted analysis. Interactions
between stigma and other variables in the final model were
examined (given the study focus on stigma) by exploring whether
their addition improved model fit.
Results
385 people were recruited of whom 5 were omitted from the
analysis as their last clinic date recorded in the ART programme
database was before their interview date. This left 380 participants
(241 female, 139 male). Of these, 362 (95.3%) started ART during
the study period with a median time to initiation from the baseline
interview of 15 days (IQR: 7–28 days). The median time in the
study was 3.35 years with a total study time at risk of 1065.81
Table 1. Cont.
Number1 (%LTFU)
LTFU rate
(per 100 p/y) Hazard Ratio2(95% CI)
P value of
association with
LTFU (LRT)
77–133 95 (30.5) 11.10 0.95 (0.57–1.59)
134–174 92 (30.4) 10.28 0.86 (0.51–1.44)
.174 94 (24.5) 8.43 0.72 (0.42–1.24)
CD4 count (binary)6 0–100 126 (32.5) 12.30 1.00 0.14
.100 251 (27.1) 9.38 (0.75 (0.51–1.10)
Migration No migration in last 2
years
214 (25.2) 8.94 1.00 0.19
Migration in last 2 years 62 (32.3) 10.49 1.17 (0.71–1.96)
Missing data 104 (33.7) 12.90 1.49 (0.98–2.28)
1n = 380 unless stated;
2Cox Regression;
3n = 356;
4n = 363;
5n = 377;
6n = 377.
doi:10.1371/journal.pone.0088235.t001
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Table 2. Univariable analysis: psychosocial variables and LTFU.
Number1
(%LTFU)
LTFU rate
(per 100 p/y)
Hazard Ratio2
(95% CI)
P value of
association
with LTFU
Stigma 0–35 83 (30.1) 10.96 1.00 0.27
36–41 82 (20.7) 7.65 0.68 (0.37–1.26)
42–47 109 (36.7) 12.81 1.12 (0.68–1.85)
48+ 106 (25.5) 8.91 0.79 (0.46–1.37)
Stigma – linear term 1.00 (0.98–1.02) 0.90
Categories of HIV disclosure 0 46 (19.6) 7.36 1.00 0.15
1 129 (26.4) 8.89 1.16 (0.56–2.41)
2 113 (28.3) 10.08 1.36(0.65–2.86)
3+ 92 (37.0) 13.94 1.90 (0.91–3.96)
Testing reason Self-initiated: non sickness 79 (36.7) 12.88 1.00 0.26
Self-initiated: sickness 234 (26.1) 9.65 0.72 (0.46–1.12)
Other initiated 67 (28.4) 9.11 0.64 (0.36–1.15)
Changed sexual behaviour No 118 (22.0) 8.35 1.00 0.20
Yes 262 (31.7) 11.00 1.32 (0.85–2.06)
Knowledge of people on ART No 96 (22.9) 8.24 1.00 0.20
Yes 284 (30.6) 10.89 1.35 (0.84–2.15)
ART knowledge Low (.=21) 93 (22.6) 7.45 1.00 0.13
Mid (22–23) 102 (31.4) 12.01 1.72 (0.99–2.98)
High (24) 185 (30.3) 10.82 1.47 (0.89–2.43)
HIV optimism3 No 110 (23.6) 8.62 1.00 0.36
Yes 266 (30.8) 10.93 1.23 (0.79–1.91)
Social support – time with family ,once a month/not at all 26 (23.1) 7.40 0.62 (0.27–1.43) 0.58
Once a month 96 (26.0) 8.96 0.73 (0.46–1.17)
At least once a fortnight 28 (35.7) 12.06 1.01 (0.52–1.96)
Several days a week 18 (33.3) 11.20 0.93 (0.40–2.16)
Every day 212 (29.2) 10.89 1.00
Social support – time with friends ,once a month/not at all 143 (23.6) 8.07 1.00 0.07
Once a month/at least once a
fortnight
70 (34.3) 10.91 1.32 (0.78–2.24)
Several days a week 88 (25.0) 9.50 1.27 (0.74–2.17)
Every day 79 (38.0) 14.63 1.98 (1.21–3.26)
Social support – rely on family/friends A little/not at all 88 (39.8) 13.18 1.00 0.10
A lot 292 (25.3) 9.25 0.71 (0.47–1.06)
Social support – open with
friends/family
Not at all 95 (17.9) 6.35 1.00 ,0.01
A little 142 (25.4) 8.43 1.34 (0.76–2.39)
A lot 143 (39.2) 15.11 2.79 (1.62–4.82)
Social support- confidant4 No 20 (30.0) 10.03 1.00 0.96
Yes 356 (28.9) 10.36 1.02 (0.45–2.33)
Social capital – time with neighbours ,once a month/not at all 150 (31.3) 10.40 1.00 0.32
At least once a fortnight/once a month 33 (18.2) 5.83 0.57 (0.24–1.33)
Several days a week 102 (28.4) 10.88 1.14 (0.72–1.81)
Every day 95 (28.4) 11.04 1.10 (0.74–1.92)
Social capital –neighbourhood crime5 Common 174 (29.3) 10.46 1.00 0.07
Unusual 109 (22.9) 7.72 0.71 (0.44–1.15)
Rare 96(33.3) 12.65 1.32 (0.84–2.05)
Social capital – group participation No 317 (29.3) 10.45 1.00 0.55
Yes 63 (25.4) 9.10 0.85 (0.51–1.45)
Social capital –neighbours giving time No 116 (30.1) 10.10 1.00 0.59
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person-years. The median age was 35 years (IQR: 29–43) and the
median CD4 count 133 cells/mm3 (IQR 76–175 cells/mm3) at
baseline.
Programme LTFU
The process of determining the LTFU outcome is presented in
Figure 1. 203 patients were retained in the programme (53.4%)
until the end of the study, 109 were LTFU (28.7%), 48 had died
and were not LTFU at the time of their death (12.6%) and 20 had
transferred out (5.3%). The overall LTFU rate was 10.65 per 100
person-years (95% CI: 8.48–12.34). Seventeen LTFU events took
place within the first 12 months of individuals’ time in the study
with the remaining 92 LTFU events occurring after 12 months.
Univariable analysis
Univariable analysis is presented in Tables 1 and 2. Stigma was
not significantly associated with LTFU, when using either stigma
score quartiles or the linear term (Table 2). Higher rates of LTFU
were related to younger age, not having children, and never
having been married (all Table 1), greater openness with family
and friends (social support), beliefs in the community working
together at a higher level to solve problems (social capital), greater
time spent with friends (social support) and less reliance on family/
friends (social support)(all Table 2).There were differences in
LTFU rates between the three clinics and levels of education
(Table 1) and between different perceptions of neighbourhood
crime (social capital: Table 2).
Multivariable analysis
In the final model, the association between LTFU and stigma
still did not reach statistical significance and there was no evidence
of a linear trend (Table 3). Higher rates of LTFU were
independently associated with lower age, male gender, not having
children, social support (greater openness with friends/family; less
reliance on family/friends) and social capital (community working
together to solve problems) (Table 3). Proportional hazards
assumptions were not violated for any of the variables in the
model or for the model as whole.
The change in estimates between the univariable and adjusted
effect of stigma on LTFU (Table 3) was apparent when number of
children was controlled in the analysis. There was no evidence that
number of children was a confounder, however, as there was not a
Table 2. Cont.
Number1
(%LTFU)
LTFU rate
(per 100 p/y)
Hazard Ratio2
(95% CI)
P value of
association
with LTFU
Yes 264 (28.0) 10.29 1.12 (0.75–1.67)
Social capital –neighbours giving
money
No 125 (29.6) 9.84 1.00 0.41
Yes 255 (28.2) 10.44 1.18 (0.79–1.76)
Social capital - community working
together6
Individual/neighbours 38 (21.1) 7.67 1.00 0.06
Traditional leaders 114 (19.3) 6.80 0.86 (0.38–1.94)
Municipal/district leaders 141 (35.5) 13.02 1.63 (0.77–3.45)
Traditional and municipal/district
leaders
86 (32.6) 11.19 1.37 (0.63–3.01)
Partnership satisfaction (amongst
those in a partnership)7
Low (0–23) 74(39.2) 13.85 1.00 0.04
Mid (24–26) 109 (28.4) 9.43 0.65 (0.39–10.7)
High (27–30) 84 (19.0) 6.81 0.46 (0.25–0.86)
Most recent partner age differential Older 214 (30.4) 10.64 1.00 0.83
Same 42 (23.8) 8.57 0.82 (0.42–1.59)
Younger 124 (27.4) 10.06 0.97 (0.64–1.47)
Most recent partner location In neighbourhood 45 (26.7) 8.90 1.00 0.64
Out of neighbourhood 174 (30.5) 11.22 1.28 (0.69–2.40)
With participant 161 (27.3) 9.59 1.11 (0.59–2.10)
Most recent partner HIV disclosure No 164 (24.4) 9.02 1.00 0.31
Yes 216 (31.9) 11.08 1.22 (0.83–1.81)
Most recent partner HIV status Positive 112 (30.4) 10.31 1.00 0.99
Not known 252 (28.2) 10.16 0.98 (0.65–1.48)
Negative 16 (25.0) 10.68 1.04 (0.37–2.92)
1n = 380 unless stated;
2Cox Regression;
3n = 376;
4n = 376;
5n = 379;
6n = 379;
7n = 267.
doi:10.1371/journal.pone.0088235.t002
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statistically significant relationship between number of children
and stigma. The change in estimates between the univariable and
adjusted effect of gender was apparent when age was controlled in
the analysis. As younger age was both related to LTFU and was
associated with female gender, there was evidence that age was a
confounder of the relationship between gender and LTFU. There
were no significant interactions between stigma and other
exposures in the final model.
Discussion
We investigated the relationship between stigma at the time of
ART eligibility and subsequent LTFU in an HIV treatment and
care programme in rural South Africa. There were weak, non-
significant associations between stigma and LTFU in univariable
and adjusted analysis. The study was adequately powered to detect
such relationships [39,40] and stigma was measured using a multi-
item scale that was internally consistent, covered different aspects
of the construct and was normally distributed.
The lack of statistically significant findings may reflect the
impact of high levels of social exposure to HIV in the area where
the study took place [26], which could have reduced levels of
stigma as well as the effect of stigma on LTFU. Alternatively, it
may be that higher levels of stigma are related to lower rates of
LTFU in some situations. For example, anticipated stigma related
to HIV disclosure in the community may motivate individuals to
seek support from HIV professionals. Conversely, anticipated
stigma may be related to higher rates in other situations, for
example, when engagement in care leads to greater concerns
about experiencing discrimination from others [41].
Our findings are consistent with multifactorial models of
engagement in care, for example, the situated IMB model [19],
that cite stigma as a contextual factor but where LTFU is
predicted to be more closely related to proximal determinants of
care (such as specific beliefs about engagement). The lack of
association between stigma and LTFU in the current study may
also refect stigma affecting engagement in care differently
depending on the stage of care (e.g., more effect on HIV testing
than clinic attendance once eligibility has been assessed).
The study revealed a number of independent LTFU predictors.
As in other studies, younger age and male gender was associated
with greater LTFU (e.g., [3,7]). There is a need to engage younger
people and men in HIV care, perhaps using targeted interventions
(e.g., community support, [42]; patient tracing, [43]; patient
advocates, [44]; mobile phone prompts, [45]; increased staff
contact, [46] or opening clinics out of hours). The mechanism by
which these factors (age, gender and parenthood) may impact
upon LTFU (e.g., effects on specific beliefs about care) needs to be
clarified.
Two aspects of social support, relying less on family/friends and
being more open with friends and family were independently
associated with higher rates of LTFU. Our findings are consistent
with social support being a multidimensional concept. Indeed
there was no correlation between reliance on family/friends and
Table 3. Final multivariable model of associations with loss to follow-up (n = 379).
Hazard Ratio
P value of association
with LTFU (LRT)
Adjusted Hazard
Ratio
P value of
association with
LTFU (LRT)
Stigma 0–35 1.00 0.28 1.00 0.06
36–41 0.68 (0.37–1.26) 0.77 (0.41–1.46)
42–47 1.12 (0.68–1.85) 1.20 (0.71–2.04)
48+ 0.77 (0.45–1.34) 0.62 (0.35–1.11)
Age 0.96 (0.94–0.98) ,0.01 0.96 (0.93–0.99) ,0.01
Gender Female 1.00 0.41 1.00 ,0.01
Male 1.18 (0.80–1.74) 2.12 (1.36–3.31)
Social support – open with
friends/family
Not at all 1.00 ,0.01 1.00 ,0.01
A little 1.32 (0.74–2.35) 1.34 (0.74–2.42)
A lot 2.78 (1.61–4.81) 3.88 (2.17–6.92)
Number of children None 1.00 0.02 1.00 0.01
1 child 0.45 (0.22–0.91) 0.28 (0.13–0.58)
2 children 0.44 (0.23–0.86) 0.48 (0.24–0.96)
3 children 0.69 (0.36–1.33) 0.69 (0.34–1.38)
4+ children 0.35 (0.19–0.67) 0.41 (0.19–0.86)
Social capital - community
working together
Individual/neighbours 1.00 0.06 1.00 0.02
Traditional leaders 0.86 (0.38–1.94) 1.64 (0.71–3.84)
Municipal/district leaders 1.63 (0.77–3.45) 2.52 (1.16–5.47)
Traditional and municipal/
district leaders
1.37 (0.63–3.01) 3.06 (1.31–7.17)
Social support – rely on
family/friends
A little/not at all 1.00 0.11 1.00 0.01
A lot 0.70 (0.47–1.05) 0.53 (0.34–0.83)
doi:10.1371/journal.pone.0088235.t003
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openness with family/friends. One common distinction in the
literature is between instrumental and emotional social support [47]. It
may be that the ‘rely’ question relates to instrumental social
support (e.g., more reliance equating with practical help in
attending clinic) and the ‘open’ question to emotional support
(with more emotional social support from family and friends
meaning that there is less need to attend clinic for staff to serve this
function). Future research could assess social support more
comprehensively to explore the relationship between this construct
and LTFU. Social capital, as measured by asking about who
would work together to solve a community problem was associated
with LTFU. However, no other aspects of social capital were
associated with LTFU and, therefore, evidence of a relationship
between this factor and LTFU is equivocal.
The wide range of variables assessed, the prospective nature of
the design, the small amount of missing data and the long follow-
up period were strengths of the study. One particular strength was
the effort made to minimise ascertainment bias (e.g., participant
tracking and cross-checking outcomes between databases). This is
consistent with the lower rate of mortality compared to LTFU in
our study.
In terms of study limitations, the number of treatment literacy
sessions attended at baseline (which may have been affected stigma
levels) was not recorded. Some of the time-varying exposures may
have changed over the duration of the study (e.g., self-reported
stigma). In addition, both baseline and intervening unmeasured
factors may have influenced whether patients were LTFU at the
end of the study period (such as beliefs about the consequences of
attending clinic, ART counselling, ambivalence about care, self-
efficacy, the nature of the patient-provider relationship, mood,
alcohol, travel costs and distance from clinic, HIV couple
discordance, and ART adherence). Some of these factors (e.g.,
counselling) may also have been related to stigma over the study
period, which may have biased the estimate of the association
between stigma and LTFU. Finally, we acknowledge that as our
measure of self-reported stigma was adapted for the study, (a) there
may have been measurement error (b) it may not possible to
directly compare the level of stigma in the sample with other
populations.
In relation to external validity, demographic characteristics
(e.g., gender and age) and clinical characteristics (e.g., CD4 count
at baseline) were similar to those reported for the programme as a
whole [48,49] and to other SSA samples [50,51]. As treatment
guidelines become more inclusive, however, our sample will be less
similar to future populations of those eligible for ART. The
context and nature of the programme may also differentiate our
sample from other populations, due to significant social exposure
to ART in the region [26], and extensive programme patient
tracking efforts. The influence of these factors on levels of stigma
and their relation to LTFU remains unknown.
In summary, this study showed that that stigma was not strongly
related to HIV treatment and care programme LTFU over a four
year period in an area of high HIV prevalence and ART use. The
presence of independent LTFU relationships with other demo-
graphic and psychosocial factors, however, is of importance given
the need to retain large numbers of HIV positive individuals in
long-term care and the potential for interventions to be developed
that focus on LTFU risk factors.
Acknowledgments
We would like to thank the individuals who participated in the study,
Nompilo Myeni, Thabile Hlabisa, Nompilo Buthelezi, T.T. Khumalo,
Khetiwhe Ngobese, Witness Ndlovu and Patrick Gabela (the study team),
Department of Health clinic staff and Colin Newell.
Author Contributions
Conceived and designed the experiments: ME MLN NM. Performed the
experiments: ME NM. Analyzed the data: ME NM. Contributed reagents/
materials/analysis tools: ME NM. Wrote the paper: ME MLN LR NM.
References
1. UNAIDS (2009) South Africa: Country Situation.
2. Shisana O (2013) HIV/AIDS in South Africa: At last the Glass is Half Full.
South Africa Aids Conference. Durban, South Africa.
3. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010)
Temporal changes in programme outcomes among adult patients initiating
antiretroviral therapy across South Africa, 2002–2007. Aids 24: 2263–2270.
4. Rosen S, Fox MP (2011) Retention in HIV Care between Testing and
Treatment in Sub-Saharan Africa: A Systematic Review. Plos Medicine 8.
5. Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F, Newell ML (2013)
Retention in Care Up to ART initiation within a Decentralized HIV
Programme in South Africa: the critical role of the 1st clinic visit. CROI.
Atlanta, USA.
6. Fox MP, Rosen S (2010) Patient retention in antiretroviral therapy programs up
to three years on treatment in sub-Saharan Africa, 2007–2009: systematic
review. Tropical Medicine & International Health 15 Suppl 1: 1–15.
7. Togun T, Peterson I, Jaffar S, Oko F, Okomo U, et al. (2011) Pre-treatment
mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually
infected patients eligible for antiretroviral therapy in The Gambia, West Africa.
Aids Research and Therapy 8.
8. Mutevedzi PC, Lessells RJ, Newell ML (2013) Disengagement from care in a
decentralised primary health care antiretroviral treatment programme: cohort
study in rural South Africa. Trop Med Int Health 18: 934–941.
9. Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, et al. (2011)
Correcting for Mortality Among Patients Lost to Follow Up on Antiretroviral
Therapy in South Africa: A Cohort Analysis. Plos One 6.
10. Karcher H, Omondi A, Odera J, Kunz A, Harms G (2007) Risk factors for
treatment denial and loss to follow-up in an antiretroviral treatment cohort in
Kenya. Tropical Medicine & International Health 12: 687–694.
11. Bassett IV, Chetty S, Wang BX, Mazibuko M, Giddy J, et al. (2012) Loss to
Follow-Up and Mortality Among HIV-Infected People Co-Infected With TB at
ART Initiation in Durban, South Africa. Jaids-Journal of Acquired Immune
Deficiency Syndromes 59: 25–30.
12. Tayler-Smith K, Zachariah R, Manzi M, Kizito W, Vandenbulcke A, et al.
(2011) Demographic characteristics and opportunistic diseases associated with
attrition during preparation for antiretroviral therapy in primary health centres
in Kibera, Kenya. Tropical Medicine & International Health 16: 579–584.
13. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, et al. (2010) Patient
Retention and Adherence to Antiretrovirals in a Large Antiretroviral Therapy
Program in Nigeria: A Longitudinal Analysis for Risk Factors. Plos One 5.
14. Wang BX, Losina E, Stark R, Munro A, Walensky RP, et al. (2011) Loss to
follow-up in a community clinic in South Africa - roles of gender, pregnancy and
CD4 count. Samj South African Medical Journal 101: 253–257.
15. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R (2009) The impact of
gender and income on survival and retention in a South African antiretroviral
therapy programme. Tropical Medicine & International Health 14: 722–731.
16. Bygrave H, Kranzer K, Hilderbrand K, Whittal J, Jouquet G, et al. (2010)
Trends in Loss to Follow-Up among Migrant Workers on Antiretroviral
Therapy in a Community Cohort in Lesotho. Plos One 5.
17. Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, et al. (2013) Toward
an Understanding of Disengagement from HIV Treatment and Care in Sub-
Saharan Africa: A Qualitative Study. Plos Medicine 10.
18. Earnshaw VA, Chaudoir SR (2009) From conceptualizing to measuring HIV
stigma: a review of HIV stigma mechanism measures. AIDS Behav 13: 1160–
1177.
19. Amico KR (2011) A situated-Information Motivation Behavioral Skills Model of
Care Initiation and Maintenance (sIMB-CIM): An IMB Model Based Approach
to Understanding and Intervening in Engagement in Care for Chronic Medical
Conditions. Journal of Health Psychology 16: 1071–1081.
20. Kalichman SC, Simbayi LC (2003) HIV testing attitudes, AIDS stigma, and
voluntary HIV counselling and testing in a black township in Cape Town, South
Africa. Sexually Transmitted Infections 79: 442–447.
21. Dlamini PS, Wantland D, Makoae LN, Chirwa M, Kohi TW, et al. (2009) HIV
Stigma and Missed Medications in HIV-Positive People in Five African
Countries. Aids Patient Care and Stds 23: 377–387.
22. McGrath N, Richter L, Newell ML (2011) Design and methods of a longitudinal
study investigating the impact of antiretroviral treatment on the partnerships and
sexual behaviour of HIV-infected individuals in rural KwaZulu-Natal, South
Africa. Bmc Public Health 11.
Stigma and Loss-to-Follow Up in HIV Treatment
PLOS ONE | www.plosone.org 9 February 2014 | Volume 9 | Issue 2 | e88235
23. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML (2013) High Coverage
of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-
Natal, South Africa. Science 339: 966–971.
24. Zaidi J, Grapsa E, Tanser F, Newell ML, Barnighausen T (2013) Dramatic
increases in HIV prevalence after scale-up of antiretroviral treatment: a
longitudinal population-based HIV surveillance study in rural kwazulu-natal.
AIDS.
25. Herbst AJ, Mafojane T, Newell ML (2011) Verbal autopsy-based cause-specific
mortality trends in rural KwaZulu-Natal, South Africa, 2000–2009. Popul
Health Metr 9: 47.
26. Bor J, Barnighausen T, Newell C, Tanser F, Newell ML (2011) Social exposure
to an antiretroviral treatment programme in rural KwaZulu-Natal. Tropical
Medicine & International Health 16: 988–994.
27. Peoples A, Barnighausen T (2008) A descriptive assessment of disclosure among
ART patients in rural South Africa. 3rd Annual Global Health Symposium.
University of Michigan, Ann Arbor, USA.
28. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, et al. (2011)
Cohort Profile: Hlabisa HIV Treatment and Care Programme. International
Journal of Epidemiology 40: 318–326.
29. Health Do (2004) National Antiretroviral Treatment Guidelines.
30. Health Do (2010) The South African Antiretroviral Treatment Guidelines.
31. (SANAC) SANAC (2011) Statement of the meeting of the South African
National AIDS Council.
32. Sayles JN, Hays RD, Sarkisian CA, Mahajan AP, Spritzer KL, et al. (2008)
Development and psychometric assessment of a multidimensional measure of
internalized HIV stigma in a sample of HIV-positive adults. AIDS Behav 12:
748–758.
33. Myer L, Stein DJ, Grimsrud A, Seedat S, Williams DR (2008) Social
determinants of psychological distress in a nationally-representative sample of
South African adults. Soc Sci Med 66: 1828–1840.
34. De Silva MJ, Harpham T, Tuan T, Bartolini R, Penny ME, et al. (2006)
Psychometric and cognitive validation of a social capital measurement tool in
Peru and Vietnam. Soc Sci Med 62: 941–953.
35. Pronyk PM, Harpham T, Morison LA, Hargreaves JR, Kim JC, et al. (2008) Is
social capital associated with HIV risk in rural South Africa? Soc Sci Med 66:
1999–2010.
36. Elford J, Ibrahim F, Bukutu C, Anderson J (2007) Sexual behaviour of people
living with HIV in London: implications for HIV transmission. Aids 21 Suppl 1:
S63–70.
37. StataCorp (2009) Stata Statistical Software: Release 11. College Station, TX:
StataCorp LP.
38. Hills M, De Stavola BL (2009) A short introduction to stata for biostatistics:
Timberlake.
39. Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events
per independent variable in proportional hazards regression analysis .2.
Accuracy and precision of regression estimates. Journal of Clinical Epidemiology
48: 1503–1510.
40. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation
study of the number of events per variable in logistic regression analysis. Journal
of Clinical Epidemiology 49: 1373–1379.
41. Holzemer WL, Uys L, Makoae L, Stewart A, Phetlhu R, et al. (2007)
A conceptual model of HIV/AIDS stigma from five African countries. J Adv
Nurs 58: 541–551.
42. Zachariah R, Teck R, Buhendwa L, Fitzerland M, Labana S, et al. (2007)
Community support is associated with better antiretroviral treatment outcomes
in a resource-limited rural district in Malawi. Transactions of the Royal Society
of Tropical Medicine and Hygiene 101: 79–84.
43. McMahon JH, Elliott JH, Hong SY, Bertagnolio S, Jordan MR (2013) Effects of
Physical Tracing on Estimates of Loss to Follow-Up, Mortality and Retention in
Low and Middle Income Country Antiretroviral Therapy Programs: A
Systematic Review. Plos One 8.
44. Fatti G, Grimwood A, Shea J (2012) Community-based adherence support
associated with improved virological suppression in adults receiving antiretro-
viral treatment: five-year outcoems from a multicentre cohort study in South
Africa. International AIDS Conference. Washington DC: USA.
45. Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, et al. (2010) Using
Mobile Phones to Improve Clinic Attendance Amongst an Antiretroviral
Treatment Cohort in Rural Uganda: A Cross-sectional and Prospective Study.
Aids and Behavior 14: 1347–1352.
46. Braitstein P, Siika A, Hogan J, Kosgei R, Sang E, et al. (2012) A clinician-nurse
model to reduce early mortality and increase clinic retention among high-risk
HIV-infected patients initiating combination antiretroviral treatment. Journal of
the International Aids Society 15.
47. Wills TA, editor (1991) Social support and interpersonal relationships. 265–289
p.
48. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, et al. (2010)
Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal,
South Africa: does rapid expansion affect patient outcomes? Bulletin of the
World Health Organization 88: 593–600.
49. Mutevedzi PC, Lessells RJ, Newell ML (unpublished) Loss to follow-up from a
decentralised primary health care antiretroviral treatment programme: cohort
study in rural South Africa.
50. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. (2011) Four-
Year Treatment Outcomes of Adult Patients Enrolled in Mozambique’s Rapidly
Expanding Antiretroviral Therapy Program. Plos One 6.
51. Somi G, Keogh SC, Todd J, Kilama B, Wringe A, et al. (2012) Low mortality
risk but high loss to follow-up among patients in the Tanzanian national HIV
care and treatment programme. Tropical Medicine & International Health 17:
497–506.
Stigma and Loss-to-Follow Up in HIV Treatment
PLOS ONE | www.plosone.org 10 February 2014 | Volume 9 | Issue 2 | e88235
